NYSEAMERICAN:SYN Synthetic Biologics (SYN) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free SYN Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,700 shsAverage Volume197,338 shsMarket Capitalization$16.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Synthetic Biologics alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Synthetic Biologics Stock (NYSEAMERICAN:SYN)Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.Read More Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. SYN Stock News HeadlinesApril 26, 2024 | finance.yahoo.comRegenerative Medicine Market Size Expected to Reach USD 154.05 Bn by 2033April 24, 2024 | finance.yahoo.comGenScript Singapore's Open Day Reveals Pioneering AI Capabilities in Recombinant Protein Production and Drug DiscoveryApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 23, 2024 | finance.yahoo.comActive Pharmaceutical Ingredient Market Trends Signal Growth Towards USD 446.6 Billion by 2032 With CAGR AT 6.4%April 23, 2024 | markets.businessinsider.comTheriva Biologics Announces Positive Data From Phase 1 Trial Of VCN-01 In Intraocular RetinoblastomaApril 22, 2024 | msn.comElon Musk rejects Tucker Carlson’s viral alien conspiracy theoryApril 19, 2024 | markets.businessinsider.comAziyo Biologics Poised for Growth: Buy Rating Affirmed Amidst Anticipated FDA Clearance and Strong Financial OutlookApril 17, 2024 | finance.yahoo.comX-Therma Announces XT-Thrive® Drug Master File (DMF) Accepted by U.S. Food and Drug Administration (FDA)April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 17, 2024 | finance.yahoo.comMustGrow Biologics to Present at the Planet MicroCap ShowcaseApril 10, 2024 | msn.com31 Netizens Share What They Consider To Be Next Big Changes In The Culture Of The InternetApril 7, 2024 | businesswire.comAffini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR ...April 3, 2024 | finance.yahoo.comSix Arizona Startups Driving Biosciences Forward in 2024April 2, 2024 | finance.yahoo.comRetinitis Pigmentosa Market to Grow Rapidly at a CAGR of 16.8% by 2034 | DelveInsightApril 2, 2024 | tmcnet.comBCC Research Reveals Top Ten Suppliers of Synthetic Biology Technology in 2024March 30, 2024 | finance.yahoo.comPharmaceutical Membrane Filtration Market is Expected to Reach $19.6 billion | MarketsandMarkets™March 27, 2024 | markets.businessinsider.comBuy Recommendation for Theriva Biologics Backed by Promising Oncolytic Adenovirus Platform and Clinical Trial AdvancementsMarch 26, 2024 | msn.comWhy Is Your Pubic Hair Itchy—and How Can You Treat It?March 25, 2024 | msn.comUpdated recommendations for psoriatic arthritisMarch 23, 2024 | msn.comHumacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | markets.businessinsider.com6 Analysts Assess Absci: What You Need To KnowMarch 19, 2024 | msn.comSamsung Life Science Fund invests in Massachusetts-based BrickBioMarch 18, 2024 | yahoo.comWhat Is Pustular Psoriasis?March 18, 2024 | finance.yahoo.comGRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development OfficerMarch 18, 2024 | finance.yahoo.comSamsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC)March 17, 2024 | usnews.comBlinken Calls for Closer Global Cooperation on Tackling Synthetic DrugsMarch 14, 2024 | finance.yahoo.comAgricultural Biologicals Market Analysis Report 2024-2030 - Market to Reach USD 12.62 Billion by 2030, Asia-Pacific to Exhibit Rapid GrowthSee More Headlines Receive SYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synthetic Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:SYN CUSIPN/A CIK894158 Webwww.syntheticbiologics.com Phone(301) 417-4364Fax301-417-4367Employees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.14% Return on Assets-22.74% Debt Debt-to-Equity RatioN/A Current Ratio4.14 Quick Ratio4.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.95 per share Price / BookN/AMiscellaneous Outstanding Shares15,844,000Free Float15,503,000Market Cap$16.16 million OptionableNot Optionable Beta1.38 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Steven A. Shallcross CPA (Age 61)CEO, CFO, Treasurer, Corp. Sec. & Director Comp: $976.91kDr. Frank Tufaro Ph.D. (Age 67)Chief Operating Officer Vincent I. PerroneDirector of Corp. CommunicationDr. Vince WacherHead of Product and Corp. Devel.Dr. Michael KalekoSr. VP of R&DMs. Lara M. GuzmanSr. Director of Project OperationsMore ExecutivesKey CompetitorsTalpheraNASDAQ:TLPHCocrystal PharmaNASDAQ:COCPKiora PharmaceuticalsNASDAQ:KPRXAytu BioPharmaNASDAQ:AYTUVBI VaccinesNASDAQ:VBIVView All Competitors SYN Stock Analysis - Frequently Asked Questions How were Synthetic Biologics' earnings last quarter? Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) released its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.10. When did Synthetic Biologics' stock split? Synthetic Biologics's stock reverse split on Monday, July 25th 2022. The 1-10 reverse split was announced on Monday, July 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Synthetic Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synthetic Biologics investors own include Synergy Pharmaceuticals (SGYP), Tonix Pharmaceuticals (TNXP), Agenus (AGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), How do I buy shares of Synthetic Biologics? Shares of SYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:SYN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synthetic Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.